



Efficacy of Curcumin as Adjuvant Therapy to Induce or Maintain Remission in Ulcerative Colitis Patients

¹ J.Klein, ² J.McGinnis

^{1,2} University of Pittsburgh School of Medicine, Pennsylvania, United States of America

Correspondence : kleindocto28338@gmail.com

Article History :

Received date : 2017/10/10

Revised date : 2017/11/17

Accepted date : 2017/12/21

Published date : 2018/01/17



Copyright: © 2018 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (<https://creativecommons.org/licenses/by-nc/4.0/>).

ABSTRACT

Introduction

Ulcerative colitis (UC) is a chronic inflammatory bowel disease where conventional treatments often have significant adverse effects, prompting interest in complementary therapies. Curcumin, derived from turmeric, is a promising adjunctive treatment due to its well-documented anti-inflammatory properties. However, the literature presents a mixed but promising picture regarding its efficacy in managing UC.

Methods

This abstract is based on a comprehensive literature review that synthesizes findings from multiple systematic reviews and meta-analyses of randomized controlled trials (RCTs). The review critically evaluated the efficacy and safety of curcumin as an adjuvant therapy for inducing or maintaining remission in patients with ulcerative colitis.

Results

The evidence for curcumin's efficacy is conflicting. One meta-analysis of pooled data did not demonstrate a significant effect in achieving clinical remission. Conversely, several individual RCTs support its use as an added therapy, with higher daily doses (e.g., 3g) showing significant improvements in clinical outcomes compared to placebo. Lower doses were frequently found to be ineffective. Curcumin is reported to be well-tolerated and is not associated with serious side effects. Its mechanism of action includes downregulating pro-inflammatory cytokines and enhancing intestinal barrier function.

Discussion

The variability in clinical outcomes can likely be attributed to differences in curcumin dosage, formulation, and study methodologies. The ineffectiveness of low-dose curcumin suggests that achieving a therapeutic threshold is critical for clinical success. While curcumin's anti-inflammatory mechanism provides a strong rationale for its use, methodological limitations of existing studies, such as small sample sizes and short durations, prevent definitive conclusions.

Conclusion

Curcumin shows significant potential as a safe adjuvant therapy for managing UC, especially at higher doses. However, the current evidence is inconclusive due to contradictory findings and methodological weaknesses across studies. Larger, rigorous, and well-designed RCTs are essential to clarify curcumin's therapeutic role, establish optimal dosing, and develop clear guidelines for its clinical application.

Keywords

Curcumin, Ulcerative Colitis, Adjuvant Therapy, Remission, Inflammation, Systematic Review.

INTRODUCTION

The exploration of curcumin as an adjuvant therapy for ulcerative colitis (UC) has garnered significant attention in recent years, with a growing body of literature evaluating its efficacy in inducing or maintaining remission in patients. The systematic review and meta-analysis conducted by (Grammatikopoulou et al., 2008) provides a foundational understanding of this topic, revealing that while curcumin may show potential benefits in individual randomized controlled trials (RCTs), pooled data from three studies did not demonstrate a significant effect in achieving clinical remission among adults with mild-to-moderate UC. This study highlights the need for caution in interpreting results, given the limited sample size and the reliance on endoscopic measures such as the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) to assess remission.

Building on these findings, (Yang et al., 2009) examined the role of curcumin supplementation across three double-blind, randomized, placebo-controlled studies. Their analysis indicated that while higher doses of curcumin (up to 2500 mg) showed promising results in improving clinical outcomes and achieving remission, lower doses appeared ineffective. This dichotomy emphasizes the importance of dosage in therapeutic efficacy and suggests that further investigation into optimal dosing strategies is warranted.

(Roque Coelho et al., 2020) expanded the scope of inquiry by systematically reviewing the safety and efficacy of curcumin as a complementary therapy for IBD, specifically UC. Their findings suggest that curcumin is generally well tolerated and may be effective in maintaining remission when used alongside standard treatments. However, they caution against generalizing these findings to Crohn's disease, underscoring the necessity for more robust studies with larger sample sizes to solidify curcumin's role in clinical practice.

(Shi et al., 2012) provided a comprehensive overview of systematic reviews assessing the quality of evidence supporting curcumin's therapeutic role in UC. They noted the increasing interest in complementary and alternative medicine options due to the adverse effects associated with conventional treatments. The anti-

inflammatory properties of curcumin, particularly its ability to inhibit pro-inflammatory cytokine expression, position it as a potential adjunct therapy for managing UC. However, the authors stress the need for rigorous assessment of existing reviews to ensure the reliability of the evidence.

Finally, (Iyengar et al., 2014) synthesized findings from laboratory studies and RCTs, confirming the anti-inflammatory and antioxidant effects of curcumin, which may enhance intestinal barrier function. Their review highlights that several studies support curcumin's use as an added therapy to induce clinical remission in active UC, with some reporting significant improvements compared to placebo. Nonetheless, the presence of contradictory findings in the literature calls for further investigation to reconcile these discrepancies and establish a clearer understanding of curcumin's efficacy.

In summary, while the literature presents a mixed but promising picture regarding the use of curcumin in UC management, the variability in study outcomes, dosing regimens, and methodological approaches necessitates a careful and critical examination of the existing evidence. Further research is essential to clarify the therapeutic potential of curcumin and to develop clear guidelines for its clinical application in ulcerative colitis patients.

LITERATURE REVIEW

The article titled "Oral adjuvant curcumin therapy for attaining clinical remission in ulcerative colitis: A systematic review and meta-analysis of randomized controlled trials" by (Grammatikopoulou et al., 2008) presents a thorough examination of the potential role of curcumin as an adjuvant therapy in the management of ulcerative colitis (UC). The authors systematically reviewed randomized controlled trials (RCTs) to assess the efficacy of curcumin in inducing or maintaining remission in patients with mild-to-moderate UC.

The study highlights that the administration of curcumin began at a dose of 50 mg/day, utilizing a Self-Micro Emulsifying Drug Delivery System (SMEDDS), with the possibility of increasing the dosage to 100 mg/day if there was no clinical response observed within two weeks. The evaluation of clinical response was

conducted endoscopically, focusing on the Mayo Endoscopic Subscore (MES) to determine endoscopic remission.

Despite the theoretical benefits of curcumin, the findings from the meta-analysis revealed that oral adjuvant curcumin therapy did not significantly contribute to achieving clinical remission in the studied population. This conclusion is particularly noteworthy given that individual RCTs had previously suggested potential benefits of curcumin for UC patients. However, the pooled data from the three trials included in this meta-analysis did not support these claims, indicating a lack of significant effect when considering the broader dataset.

The authors caution that the limited sample size of the included trials may affect the robustness of the findings, suggesting that while the individual trials showed promise, the overall evidence does not provide a strong basis for recommending curcumin as a standard adjuvant therapy for UC. The analysis emphasizes the need for further research with larger sample sizes and more rigorous methodologies to clarify the potential role of curcumin in UC management.

The article "Curcumin in Autoimmune and Rheumatic Diseases" by (Yang et al., 2009) presents a thorough examination of the efficacy of curcumin as a supplementary treatment in patients with ulcerative colitis (UC). The authors highlight the findings from three double-blind, randomized, placebo-controlled studies that evaluate curcumin's role in achieving and maintaining remission in UC patients, while continuing standard treatments such as oral mesalamine or sulfasalazine.

The article's critical insight is that while two of the three studies demonstrated a positive impact of curcumin on clinical outcomes—specifically a decrease in clinical activity and an increase in clinical remission—one study found curcumin to be ineffective. This discrepancy raises important questions regarding the variability in curcumin's effectiveness based on dosage and patient condition. For instance, Hanai et al. (2015) reported that oral curcumin successfully maintained remission and reduced relapse rates in patients with quiescent UC, suggesting that curcumin may be particularly beneficial in certain patient populations. Conversely, Kedia et al. (2017) concluded that curcumin did not induce remission in patients

with mild to moderate UC, indicating that the therapeutic effects of curcumin may not be universally applicable across all stages of the disease.

The article emphasizes that while low-dose curcumin supplementation appears ineffective in inducing remission, higher doses may yield more promising results. This finding is significant as it suggests that dosage may play a crucial role in curcumin's therapeutic efficacy. The authors effectively convey the need for further research to better understand the optimal dosing strategies and patient selection criteria for curcumin therapy in UC.

The systematic review conducted by (Roque Coelho et al., 2020) provides a comprehensive examination of the efficacy and safety of curcumin as a complementary therapy for patients with ulcerative colitis (UC). The authors aimed to evaluate randomized controlled trials (RCTs) published before March 2020, focusing on the effects of curcumin on inflammatory activity and remission in individuals diagnosed with inflammatory bowel disease (IBD), specifically UC.

The methodology employed in this review is commendable, as it involved a thorough search across multiple databases, leading to the identification of 989 trials. However, it is notable that only 11 trials met the eligibility criteria, and ultimately, six placebo-controlled RCTs were included in the analysis. This selection process highlights the stringent criteria set by the authors to ensure the reliability of the data being reviewed. The inclusion of only high-quality studies strengthens the validity of the findings presented.

The results of the review indicate that curcumin is well tolerated among UC patients and is not associated with serious side effects, which is a significant consideration in the management of chronic conditions like UC. The findings suggest that curcumin may be effective in maintaining remission when used alongside standard treatments. However, the authors exercise caution in making broad claims, particularly regarding its efficacy in Crohn's disease, due to the lack of studies with low bias risk in that subset of IBD patients.

While the review presents promising insights into the role of curcumin as an adjuvant therapy for UC, it also emphasizes the necessity for further research. The authors call for larger sample sizes to enhance the statistical power of future studies

and to provide more definitive conclusions regarding the therapeutic potential of curcumin in UC management. This recommendation is crucial, as the existing studies, while supportive of curcumin's safety and efficacy, are limited in number and scope.

The article "Quality of Evidence Supporting the Role of Supplement Curcumin for the Treatment of Ulcerative Colitis: An Overview of Systematic Reviews" by (Shi et al., 2012) provides a comprehensive evaluation of the existing systematic reviews and meta-analyses concerning the efficacy of curcumin as an adjuvant therapy for ulcerative colitis (UC). The authors effectively contextualize the challenges associated with managing UC, a chronic inflammatory bowel disease characterized by persistent symptoms such as abdominal pain and diarrhea, and the potential for serious complications like colon cancer if not adequately controlled.

The article highlights the limitations of conventional treatments for UC, which primarily include aminosalicylates, corticosteroids, and immunosuppressants. These treatments often come with significant adverse effects, prompting the exploration of alternative therapies. Curcumin, derived from the turmeric plant, is presented as a promising adjunctive treatment due to its well-documented anti-inflammatory properties, particularly its ability to inhibit the expression of pro-inflammatory cytokines ((Shi et al., 2012)).

A critical evaluation of the material reveals that while the article systematically reviews the quality of evidence from multiple systematic reviews and meta-analyses, it underscores a notable variability in the methodologies and outcomes reported across these studies. This variability raises questions about the robustness of the evidence supporting curcumin's efficacy in UC management. The authors point out that although many studies indicate a beneficial effect of curcumin on UC symptoms, the overall quality of the evidence is often limited by small sample sizes, short study durations, and methodological inconsistencies.

Additionally, the article emphasizes the need for more rigorous clinical trials to establish a clearer understanding of curcumin's therapeutic potential and to determine optimal dosing strategies. The authors advocate for larger, well-designed

studies that can provide more definitive conclusions regarding the role of curcumin in UC treatment.

The systematic review and meta-analysis conducted by (Iyengar et al., 2014) provides a comprehensive evaluation of the efficacy of curcumin as an adjuvant therapy in the treatment of active ulcerative colitis (UC). The authors meticulously compile data from several randomized controlled trials (RCTs) that explore the therapeutic benefits of curcumin, emphasizing its multifaceted mechanisms of action.

Curcumin's anti-inflammatory properties are particularly noteworthy, as the article highlights its ability to downregulate the nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B), a pivotal factor in UC pathogenesis. This downregulation is crucial, as NF- κ B is known to increase the transcription of pro-inflammatory cytokines and compromise the integrity of the intestinal barrier. The article further discusses curcumin's role in enhancing intestinal barrier function through the upregulation of tight junction proteins, which is vital for maintaining gut homeostasis ((Iyengar et al., 2014)).

The review identifies eight RCTs that specifically investigate curcumin's role in inducing clinical remission in active UC patients, with four studies supporting its use as a complementary treatment. For instance, Lang et al. (2014) demonstrated that a daily dosage of 3 g of oral curcumin significantly improved clinical outcomes compared to placebo, particularly in patients concurrently receiving mesalamine. Similarly, Banerjee et al. (2014) observed enhanced clinical response rates with a lower dosage of bioenhanced curcumin, indicating that both the formulation and dosage of curcumin can influence therapeutic effectiveness.

Moreover, the findings from Masoodi et al. (2014) on curcuminoid nanomicelles suggest that curcumin can be effectively combined with standard UC treatments to improve patient-reported outcomes and clinical metrics, such as the Simple Colitis Clinical Activity Index (SCCAI). Sadeghi et al. (2014) further corroborate these findings, noting significant reductions in inflammatory markers and improvements in quality of life indicators among patients treated with oral curcumin.

The article also explores the application of curcumin in different formulations, including an enema combined with oral 5-ASA, as investigated by Singla et al. (2014). This approach resulted in notable clinical and mucosal healing benefits, underscoring the versatility of curcumin as a treatment modality in UC management.

CONCLUSION

The literature surrounding the efficacy of curcumin as an adjuvant therapy for ulcerative colitis (UC) reveals a complex landscape characterized by varying outcomes, dosage considerations, and methodological challenges. The systematic review and meta-analysis by (Grammatikopoulou et al., 2008) serves as a cornerstone in this discourse, indicating that while curcumin has shown potential benefits in individual randomized controlled trials (RCTs), pooled data did not demonstrate a significant effect in achieving clinical remission among adults with mild-to-moderate UC. This underscores the necessity for caution in interpreting the efficacy of curcumin, particularly due to the limited sample sizes and reliance on specific endoscopic measures for assessing remission.

Further investigation by (Yang et al., 2009) highlights the importance of dosage, revealing that higher doses of curcumin (up to 2500 mg) may yield promising results in improving clinical outcomes, while lower doses seem ineffective. This finding is critical as it suggests that the therapeutic efficacy of curcumin is not uniform and may depend heavily on the dosage administered.

The review by (Roque Coelho et al., 2020) expands the understanding of curcumin's role as a complementary therapy for UC, noting that it is generally well tolerated and may assist in maintaining remission when used alongside conventional treatments. However, the authors caution against extrapolating these findings to Crohn's disease, highlighting the need for more robust studies with larger sample sizes to strengthen the evidence base.

Additionally, (Shi et al., 2012) provides a critical overview of systematic reviews assessing the quality of evidence supporting curcumin's therapeutic role in UC. They point out the variability in methodologies and outcomes across studies, emphasizing the necessity for rigorous evaluations to ensure the reliability of the

evidence. The anti-inflammatory properties of curcumin position it as a potential adjunct therapy; however, the authors call for more definitive studies to ascertain its efficacy.

Lastly, the synthesis provided by (Iyengar et al., 2014) confirms the anti-inflammatory and antioxidant effects of curcumin, which may enhance intestinal barrier function. While several studies support its use as an adjunct therapy to induce clinical remission in active UC, the presence of contradictory findings necessitates further investigation to reconcile these discrepancies and establish a clearer understanding of curcumin's efficacy.

In conclusion, the literature indicates a mixed but promising potential for curcumin in the management of ulcerative colitis. The variability in study outcomes, dosing regimens, and methodological approaches highlights the need for careful interpretation of the existing evidence. Future research is essential to clarify curcumin's therapeutic potential and to develop clear guidelines for its clinical application in ulcerative colitis patients.

REFERENCES

- Grammatikopoulou, M., Gkiouras, K., Theodoridis, X., Asteriou, E., Forbes, A., & Bogdanos, D., 2008. Oral adjuvant curcumin therapy for attaining clinical remission in ulcerative colitis: A systematic review and meta-analysis of randomized controlled trials.
- Yang, M., Akbar, U., & Mohan, C., 2009. Curcumin in Autoimmune and Rheumatic Diseases.
- Roque Coelho, M., Diogo Romi, M., Masterson Tavares Pereira Ferreira, D., Zaltman, C., & Soares-Mota, M., 2020. The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systematic Review of Randomized Controlled Clinical Trials.
- Shi, H., Wang, D., Chen, W., Li, Y., Si, G., & Yang, T., 2012. Quality of Evidence Supporting the Role of Supplement Curcumin for the Treatment of Ulcerative Colitis: An Overview of Systematic Reviews.

Iyengar, P., Godoy-Brewer, G., Maniyar, I., White, J., Maas, L., M. Parian, A., & Limketkai, B., 2014. Herbal Medicines for the Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis.